TPD the C4T Way
Since our founding in 2015, we have established ourselves as a leader in targeted protein degradation science (TPD), with a world-class platform shown to produce oral medicines that are highly active against their desired targets. With several oral oncology degraders in clinical development, our research is focused on advancing the next wave of targets to include those which have previously been considered undruggable.
Key elements of our approach to TPD include:
- Focus on catalytic efficiency
- Investment in Cereblon as E3 ligase
By focusing on catalytic efficiency and leveraging Cereblon, we have built capabilities unique to the TPD field. At C4 Therapeutics, we can:
- Design, analyze and predict degrader performance
- Develop MonoDAC™ and BiDAC™ degraders
